Tag : PROGNOSTIC FACTORS

CONFERENCE UPDATE

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2
In the phase 3 FLAURA2 study, osimertinib + platinum-pemetrexed demonstrated statistically significant improvements in progression-free survival and overall survival vs. osimertinib monotherapy in epidermal growth factor receptor-mutated advanced non-small cell lung cancer, achieving a median OS of 47.5 months.